Blood Cancer Therapy – BiotechReality – Information Intelligence System for Biopharma

The United States FDA grants accelerated approval for Pfizer's therapy for the treatment of blood cancer (type)-affected patients which is difficult to treat. "On August 14, 2023, the Food and Drug Administration granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody." -FDA In the MagnetisMM-3 (NCT04649359) research, patients with relapsed/refractory multiple sclerosis (MS) who had failed at least one proteasome inhibitor, one immunomodulatory medication, and one anti-CD38 antibody had their efficacy assessed. According to International Myeloma Working Group (IMWG) standards, patients had detectable disease at enrollment. FDA approved the initiatory oral pill treatment for Postpartum Depression (PPD) Other competitive antibody medicines include Roche's Columvi (ROG.S), Abbvie's Epkinly (ABBV.N), and Johnson & Johnson's (JNJ.N) Talvey recently approved. Data from mid-stage research, which revealed that 58% of patients treated with Pfizer's treatment had no symptoms of cancer or had experienced a significant decline in cancer cells in the body, served as the foundation for the FDA's approval. A malignancy known as multiple myeloma develops in a type of white blood cell known as a plasma cell. Healthy plasma cells produce antibodies that bind to and destroy bacteria, assisting your body in fighting illnesses. Cancerous plasma cells build up in the bone marrow and crowd out healthy blood cells in multiple myeloma. Source: FDA, Reuters Image Source: FDA

Tag: Blood Cancer Therapy

FDA grants approval for the blood cancer therapy of Pfizer

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment